ReviewChest2016
Crises in Sickle Cell Disease.
Review in Chest, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 5 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- Systematic review of machine learning approaches for predicting sickle cell crisis and mortality risk at the climate-health nexus.BMC medical informatics and decision making · 2026Pooled it
- Pooled it
- Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis.BMJ open · 2020Pooled it
- Antibiotics for treating acute chest syndrome in people with sickle cell disease.The Cochrane database of systematic reviews · 2019Pooled it
- A Meta-Analysis on the Seroprevalence of Parvovirus B19 among Patients with Sickle Cell Disease.BioMed research international · 2019Pooled it
- Low educational level of head of household, as a proxy for poverty, is associated with severe anaemia among children with sickle cell disease living in a low-resource setting: evidence from the SPRING trial.British journal of haematology · 2020Trial
- Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease.Clinical pharmacokinetics · 2019Trial
- Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study.British journal of haematology · 2019Trial
- A dose-ranging study of ticagrelor in children aged 3-17 years with sickle cell disease: A 2-part phase 2 study.American journal of hematology · 2018Trial
- Hydroxyurea reduces hyperadhesion measured by a VLA-4-targeting PET tracer in sickle transgenic Townes mice.Blood advances · 2026Article
- Biomarkers for the diagnosis and phenotyping of acute chest syndrome in patients with sickle cell disease.Expert review of respiratory medicine · 2026Review
- Prevalence of Depression and Suicidality Among Children and Adolescents with Sickle Cell Anaemia in Eastern Uganda.Research square · 2026Article
- Health-related quality of life among patients with sickle cell disease in the hereditary blood disease center in Saudi Arabia.Medicine · 2026Article
- Development of a Novel Patient-Reported Outcome Diary to Capture and Monitor Home-Managed Pain Crises in Patients with Sickle Cell Disease.Advances in therapy · 2026Article
- Narratives unveil knowledge and awareness-related issue, reinforcing patients' self-identity in sickle cell disease.Orphanet journal of rare diseases · 2026Article
- Singularity in nonlinear systems: differential inclusion model for the standard and transformed fractional pantograph equation.Scientific reports · 2026Article
- Transforming sickle cell haemotherapy in Africa: building safe, antigen-matched, available, and sustainable transfusion pathways.Frontiers in medicine · 2026Review
- The correlation of lupus anticoagulant and anticardiolipin antibodies with hematological parameters and clinical findings in sickle cell disease at steady state phase.Thrombosis journal · 2025Article
- Severe parvovirus B19 infection in patients with sickle cell disease hospitalized in intensive care units.Blood advances · 2025Observational
- Emergency care for children with sickle cell disease: a focus on pain and fever.Expert review of hematology · 2025Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In spite of significant strides in the treatment of sickle cell disease (SCD), SCD crises are still responsible for high morbidity and early mortality. While most patients initially seek care in the acute setting for a seemingly uncomplicated pain episode (pain crisis or vaso-occlusive crisis), this initial event is the primary risk factor for potentially life-threatening complications. The pathophysiological basis of these illnesses is end-organ ischemia and infarction combined with the downstream effects of hemolysis that results from red blood cell sickling. These pathological changes can occur acutely and lead to a dramatic clinical presentation, but are frequently superimposed over a milieu of chronic vasculopathy, immune dysregulation, and decreased functional reserve. In the lungs, acute chest syndrome is a particularly ominous lung injury syndrome with a complex pathogenesis and potentially devastating sequelae, but all organ systems can be affected. It is, therefore, critical to understand the SCD patients' susceptibility to acute complications and their risk factors so that they can be recognized promptly and managed effectively. Blood transfusions remain the mainstay of therapy for all severe acute crises. Recommendations and indications for the safest and most efficient implementation of transfusion strategies in the critical care setting are therefore presented and discussed, together with their pitfalls and potential future therapeutic alternatives. In particular, the importance of extended phenotypic red blood cell matching cannot be overemphasized, due to the high prevalence of severe complications from red cell alloimmunization in SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.